How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
Both AG and MIS have benchmarked their success by capitalizing on market development and distribution of emerging cancer detection products. Dilon'smolecular diagnostics pair well with the mission of both companies, and is a major stride for realizing its international presence.
BSGI with the Dilon 6800 (BSGI) is a molecular breast imaging technique that has proven to be an effective tool in the early detection of breast cancer and in the differentiation of malignant and benign tumors. Better than its predecessor, scintimammography, BSGI relies on the advanced imaging technology of anatomic- specific detectors and superior positioning to optimize the results of functional breast imaging. Many leading medical centers around the country are now offering BSGI to their patients.
For more information, visit the company's website: http://www.dilon.com .
SOURCE Dilon Technologies, LLC
News stories provided by third parties are not edited by "Site Publication" staff. For suggestions and comments, please click the Contact link at the bottom of this page.